.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB02_Rifampicin.Rifampicin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB02_Rifampicin.Rifampicin| name: | Rifampicin |
| ATC code: | J04AB02 | route: | oral |
| n-compartments | 2 |
Rifampicin is a broad-spectrum antibiotic used primarily for the treatment of tuberculosis and leprosy. It works by inhibiting bacterial DNA-dependent RNA polymerase and is a key component of first-line anti-tuberculosis therapy. Rifampicin is currently approved and widely used in clinical practice.
Pharmacokinetic parameters reported in adult healthy volunteers following single oral administration of rifampicin.
Abulfathi, AA, et al., & Reuter, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Clinical pharmacokinetics 58(9) 1103–1129. DOI:10.1007/s40262-019-00764-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31049868
Abulfathi, AA, et al., & Svensson, EM (2021). The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. Frontiers in pharmacology 12 637618–None. DOI:10.3389/fphar.2021.637618 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34267655
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241